^
Association details:
| Biomarker: | CD38 positive |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Darzalex (daratumumab) (CD38 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PRE-TREATMENT CD38 EXPRESSION LEVELS IN MYELOMA CELLS AND CD38-POSITIVE REGULATORY T CELLS AFFECT THE RESPONSE OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TO TREATMENT WITH DARATUMUMAB
Published date:
05/17/2018
Excerpt:
We included 28 relapsed/refractory myeloma patients, who were treated with DARA....Before treatment, the absolute number of CD38-positive Treg cells was significantly higher in responders (median, 10.9/µl; range, 5.1-37.3/µl) than in non-responders (median, 4.8/μL; range, 1.1-12.8/µl, p = 0.02)…
